The report covers forecast and analysis for the erectile dysfunction drugs market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the erectile dysfunction drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the erectile dysfunction drugs market on a global level.
In order to give the users of this report a comprehensive view of the erectile dysfunction drugs market, we have included the competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug, mode of administration, distribution channel, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on the global and regional basis.
The study provides a decisive view of the erectile dysfunction drugs market by segmenting the market based on drug, mode of administration, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries.
Some of the leading players in erectile dysfunction drugs market include Apricus Biosciences, Bayer AG, Cristália, Eli Lilly and Company, Inc., Pfizer, Inc., Dong-A-Pharmaceutical Co., Ltd., S.K. Chemicals Co., Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd. and Meda Pharmaceuticals, Inc.
This report segments the global erectile dysfunction drugs market as follows:
Global Erectile Dysfunction Drugs Market: Drug Segment Analysis
- Sildenafil Citrate (Viagra)
- Vardenafil (Levitra/ Staxyn)
- Tadalafil (Cialis)
- Udenafil (Zydena)
- Lodenafil Carbonate (Helleva)
- Stendra/ Spedra (Avanafil)
- Mirodenafil (Mvix)
- Others
Global Erectile Dysfunction Drugs Market: Mode of Administration Segment Analysis
- Oral Medications
- Topical Medications
- Injections
- Others
Global Erectile Dysfunction Drugs Market: Distribution Channel Segment Analysis
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
Global Erectile Dysfunction Drugs Market: Regional Segment Analysis
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East and Africa
Table of Contents
- Chapter 1. Introduction
- 1.1. Report description and scope
- 1.2. Research scope
- 1.3. Research methodology
- 1.3.1. Market research process
- 1.3.2. Market research methodology
- Chapter 2. Executive Summary
- 2.1. Global erectile dysfunction drugs market, 2017 - 2024 (USD Billion)
- 2.2. Global erectile dysfunction drugs market : snapshot
- Chapter 3. Erectile Dysfunction Drugs Market - Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Global erectile dysfunction drugs market drivers: impact analysis
- 3.2.2. Increase in focus of key players to develop drugs for the treatment of erectile dysfunction
- 3.2.3. Presence of strong emerging pipeline drugs
- 3.2.4. Increased funding from both public and private research organizations
- 3.3. Market Restraints
- 3.3.1. Global erectile dysfunction drugs market restraints: impact analysis
- 3.3.2. Longer timelines required for the drug development
- 3.4. Opportunities
- 3.4.1. Increase in investment by market players in the emerging economies
- 3.5. Porter's five forces analysis
- 3.5.1. Bargaining power of suppliers
- 3.5.2. Bargaining power of buyers
- 3.5.3. Threat from new entrants
- 3.5.4. Threat from new substitutes
- 3.5.5. Degree of competition
- 3.6. Market Attractiveness Analysis
- 3.6.1. Market attractiveness analysis, by drug segment
- 3.6.2. Market attractiveness analysis, by mode of administration segment
- 3.6.3. Market attractiveness analysis, by distribution channel segment
- 3.6.4. Market attractiveness analysis, by regional segment
- Chapter 4. Global Erectile Dysfunction Drugs Market - Competitive Landscape
- 4.1. Company market share analysis
- 4.1.1. Global erectile dysfunction drugs market : company market share, 2017
- 4.2. Strategic development
- 4.2.1. Acquisitions & mergers
- 4.2.2. New therapy launch
- 4.2.3. Agreements, partnerships, collaborations and joint ventures
- 4.2.4. Research and development and regional expansion
- 4.3. Price trend analysis
- 4.1. Company market share analysis
- Chapter 5. Global Erectile Dysfunction Drugs Market - Drug Segment Analysis
- 5.1. Global erectile dysfunction drugs market : drug overview
- 5.1.1. Global erectile dysfunction drugs market revenue share, by drug, 2017 and 2024
- 5.2. Sildenafil Citrate (Viagra)
- 5.2.1. Global erectile dysfunction drugs market for sildenafil citrate (viagra), 2017 - 2024 (USD Billion)
- 5.3. Vardenafil (Levitra/ Staxyn)
- 5.3.1. Global erectile dysfunction drugs market for vardenafil (levitra/ staxyn), 2017 - 2024 (USD Billion)
- 5.4. Tadalafil (Cialis)
- 5.4.1. Global erectile dysfunction drugs market for tadalafil (cialis), 2017 - 2024 (USD Billion)
- 5.5. Udenafil (Zydena)
- 5.5.1. Global erectile dysfunction drugs market for udenafil (zydena), 2017 - 2024 (USD Billion)
- 5.6. Lodenafil Carbonate (Helleva)
- 5.6.1. Global erectile dysfunction drugs market for lodenafil carbonate (helleva), 2017 - 2024 (USD Billion)
- 5.7. Stendra/ Spedra (Avanafil)
- 5.7.1. Global erectile dysfunction drugs market for stendra/ spedra (avanafil), 2017 - 2024 (USD Billion)
- 5.8. Mirodenafil (Mvix)
- 5.8.1. Global erectile dysfunction drugs market for mirodenafil (mvix), 2017 - 2024 (USD Billion)
- 5.9. Others
- 5.9.1. Global erectile dysfunction drugs market for others, 2017 - 2024 (USD Billion)
- 5.1. Global erectile dysfunction drugs market : drug overview
- Chapter 6. Global Erectile Dysfunction Drugs Market - Mode of Administration Segment Analysis
- 6.1. Global erectile dysfunction drugs market : distribution channel overview
- 6.1.1. Global erectile dysfunction drugs market revenue share, by distribution channel, 2017 and 2024
- 6.2. Oral Medications
- 6.2.1. Global erectile dysfunction drugs market for oral medications, 2017 - 2024 (USD Billion)
- 6.3. Topical Medications
- 6.3.1. Global erectile dysfunction drugs market for topical medication, 2017 - 2024 (USD Billion)
- 6.4. Injections
- 6.4.1. Global erectile dysfunction drugs market for injections, 2017 - 2024 (USD Billion)
- 6.5. Others
- 6.5.1. Global erectile dysfunction drugs market for others, 2017 - 2024 (USD Billion)
- 6.1. Global erectile dysfunction drugs market : distribution channel overview
- Chapter 7. Global Erectile Dysfunction Drugs Market - Distribution Channel Segment Analysis
- 7.1. Global erectile dysfunction drugs market : distribution channel overview
- 7.1.1. Global erectile dysfunction drugs market revenue share, by distribution channel, 2017 and 2024
- 7.2. Hospital Pharmacies
- 7.2.1. Global erectile dysfunction drugs market for hospital pharmacies, 2017 - 2024 (USD Billion)
- 7.3. Retail Pharmacies
- 7.3.1. Global erectile dysfunction drugs market for retail pharmacies, 2017 - 2024 (USD Billion)
- 7.4. Online Sales
- 7.4.1. Global erectile dysfunction drugs market for online sales, 2017 - 2024 (USD Billion)
- 7.1. Global erectile dysfunction drugs market : distribution channel overview
- Chapter 8. Global Erectile Dysfunction Drugs Market - Regional Segment Analysis
- 8.1. Global erectile dysfunction drugs market : regional overview
- 8.1.1. Global erectile dysfunction drugs market revenue share, by region, 2017 and 2024
- 8.2. North America
- 8.2.1. North America erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.2.2. North America erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.2.3. North America erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.2.4. The U.S.
- 8.2.4.1. The U.S. erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.2.4.2. The U.S. erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.2.4.3. The U.S. erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.2.5. Canada
- 8.2.5.1. Canada erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.2.5.2. Canada erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.2.5.3. Canada erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.3. Europe
- 8.3.1. Europe erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.3.2. Europe erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.3.3. Europe erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.3.4. U.K.
- 8.3.4.1. U.K. erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.3.4.2. U.K. erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.3.4.3. U.K. erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.3.5. Germany
- 8.3.5.1. Germany erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.3.5.2. Germany erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.3.5.3. Germany erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.3.6. France
- 8.3.6.1. France erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.3.6.2. France erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.3.6.3. France erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.3.7. Rest of Europe
- 8.3.7.1. Rest of Europe erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.3.7.2. Rest of Europe erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.3.7.3. Rest of Europe erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.4.2. Asia Pacific erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.4.3. Asia Pacific erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.4.4. China
- 8.4.4.1. China erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.4.4.2. China erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.4.4.3. China erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.4.5. Japan
- 8.4.5.1. Japan erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.4.5.2. Japan erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.4.5.3. Japan erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.4.6. India
- 8.4.6.1. India erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.4.6.2. India erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.4.6.3. India erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.4.7. Rest of Asia Pacific
- 8.4.7.1. Rest of Asia Pacific erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.4.7.2. Rest of Asia Pacific erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.4.7.3. Rest of Asia Pacific erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.5. Latin America
- 8.5.1. Latin America erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.5.2. Latin America erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.5.3. Latin America erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.5.4. Brazil
- 8.5.4.1. Brazil erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.5.4.2. Brazil erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.5.4.3. Brazil erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.5.5. Rest of Latin America
- 8.5.5.1. Rest of Latin America erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.5.5.2. Rest of Latin America erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.5.5.3. Rest of Latin America erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.6. The Middle East and Africa
- 8.6.1. The Middle East and Africa erectile dysfunction drugs market revenue, by drug, 2017 - 2024 (USD Billion)
- 8.6.2. The Middle East and Africa erectile dysfunction drugs market revenue, by mode of administration, 2017 - 2024 (USD Billion)
- 8.6.3. The Middle East and Africa erectile dysfunction drugs market revenue, by distribution channel, 2017 - 2024 (USD Billion)
- 8.1. Global erectile dysfunction drugs market : regional overview
- Chapter 9. Company Profile
- 9.1. Apricus Biosciences
- 9.1.1. Overview
- 9.1.2. Financials
- 9.1.3. Product portfolio
- 9.1.4. Business strategy
- 9.1.5. Recent developments
- 9.2. Bayer AG
- 9.2.1. Overview
- 9.2.2. Financials
- 9.2.3. Product portfolio
- 9.2.4. Business strategy
- 9.2.5. Recent developments
- 9.3. Cristália
- 9.3.1. Overview
- 9.3.2. Financials
- 9.3.3. Product portfolio
- 9.3.4. Business strategy
- 9.3.5. Recent developments
- 9.4. Eli Lilly and Company, Inc.
- 9.4.1. Overview
- 9.4.2. Financials
- 9.4.3. Product portfolio
- 9.4.4. Business strategy
- 9.4.5. Recent developments
- 9.5. Pfizer, Inc.
- 9.5.1. Overview
- 9.5.2. Financials
- 9.5.3. Product portfolio
- 9.5.4. Business strategy
- 9.5.5. Recent developments
- 9.6. Dong-A Pharmaceutical Co., Ltd.
- 9.6.1. Overview
- 9.6.2. Financials
- 9.6.3. Product portfolio
- 9.6.4. Business strategy
- 9.6.5. Recent developments
- 9.7. S.K. Chemicals Co., Ltd.
- 9.7.1. Overview
- 9.7.2. Financials
- 9.7.3. Product portfolio
- 9.7.4. Business strategy
- 9.7.5. Recent developments
- 9.8. Vivus, Inc.
- 9.8.1. Overview
- 9.8.2. Financials
- 9.8.3. Product portfolio
- 9.8.4. Business strategy
- 9.8.5. Recent developments
- 9.9. Teva Pharmaceutical Industries Ltd.
- 9.9.1. Overview
- 9.9.2. Financials
- 9.9.3. Product portfolio
- 9.9.4. Business strategy
- 9.9.5. Recent developments
- 9.10. Meda Pharmaceuticals, Inc.
- 9.10.1. Overview
- 9.10.2. Financials
- 9.10.3. Product portfolio
- 9.10.4. Business strategy
- 9.10.5. Recent developments
- 9.1. Apricus Biosciences
